Carmine De Angelis, Associate Professor at Southern Higher School, Naples, shared a post on LinkedIn:
“Today I had the pleasure of presenting on the clinical and molecular determinants guiding treatment decisions in HR+/HER2- metastatic breast cancer following progression on CDK4/6 inhibitors, during the Thai Society of Clinical Oncology (TSCO) Annual Meeting 2025.
My sincere thanks to Prof. Charuwan Akewanlop from Siriraj Hospital for her excellent moderation.
I’m also grateful to AstraZeneca for organizing this important and timely symposium.
It’s always a privilege to share knowledge and exchange perspectives with colleagues from around the world.”
More posts featuring Carmine De Angelis on OncoDaily.
